This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Expression of semaphorin 3A (SEMA3A) in breast cancer subtypes
Scientific Reports Open Access 23 January 2024
-
Molecular Landscape of LncRNAs in Prostate Cancer: A focus on pathways and therapeutic targets for intervention
Journal of Experimental & Clinical Cancer Research Open Access 01 July 2022
Access options
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Velez, E. M. et al. Comparative prognostic implication of treatment response assessments in mCRPC: PERCIST 1.0, RECIST 1.1, and PSA response criteria. Theranostics 10, 3254–3262 (2020).
Gillessen, S. et al. Management of patients with advanced prostate cancer: report of the advanced prostate cancer consensus conference 2019. Eur. Urol. 77, 508–547 (2020).
Di Mitri, D. et al. Re-education of tumor-associated macrophages by CXCR2 blockade drives senescence and tumor inhibition in advanced prostate cancer. Cell Rep. 28, 2156–2168.e5 (2019).
Casazza, A. et al. Impeding macrophage entry into hypoxic tumor areas by Sema3A/Nrp1 signaling blockade inhibits angiogenesis and restores antitumor immunity. Cancer Cell 24, 695–709 (2013).
Ren, S. et al. Whole-genome and transcriptome sequencing of prostate cancer identify new genetic alterations driving disease progression. Eur. Urol. 73, 322–339 (2018).
Wang, C. et al. Blocking the feedback loop between neuroendocrine differentiation and macrophages improves the therapeutic effects of enzalutamide (MDV3100) on prostate cancer. Clin. Cancer Res. 24, 708–723 (2018).
Noy, R. & Pollard, J. W. Tumor-associated macrophages: from mechanisms to therapy. Immunity 41, 49–61 (2014).
Murray, P. J. et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity 41, 14–20 (2014).
Tse, B. W. C. et al. Neuropilin-1 is upregulated in the adaptive response of prostate tumors to androgen-targeted therapies and is prognostic of metastatic progression and patient mortality. Oncogene 36, 3417 (2017).
Acknowledgements
The National Natural Science Foundation of China (81472397 to S.R. and 81773154 to C.W.). The Top-level Clinical Discipline Project of Shanghai Pudong (PWYgf2018-03, C.W.). The Shanghai Natural Science Foundation (20ZR1449600, C.W.). The Leadership Program in Science and Technology of Beijing Municipal Science and Technology Commission (181100006318007, N.X.).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing interests.
Supplementary information
Rights and permissions
About this article
Cite this article
Liu, F., Wang, C., Huang, H. et al. SEMA3A-mediated crosstalk between prostate cancer cells and tumor-associated macrophages promotes androgen deprivation therapy resistance. Cell Mol Immunol 18, 752–754 (2021). https://doi.org/10.1038/s41423-021-00637-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41423-021-00637-4
This article is cited by
-
Expression of semaphorin 3A (SEMA3A) in breast cancer subtypes
Scientific Reports (2024)
-
Molecular Landscape of LncRNAs in Prostate Cancer: A focus on pathways and therapeutic targets for intervention
Journal of Experimental & Clinical Cancer Research (2022)